載入中
NASDAQHealthcareBiotechnology
最新資料
US$8.37
−US$0.195 · -2.28%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
一般交易時段
US$8.36
−US$0.205 · -2.39%
盤中時間採用ET。市場資料可能有所延遲。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日內區間
目前US$8.36
52週區間
目前US$8.36
盤中時間採用ET。市場資料可能有所延遲。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日內區間
目前US$8.36
52週區間
目前US$8.36
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$21.33
上漲空間 155.14%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1595.19萬0.00%2.3兆 USD0.03%US$381.05-0.14%
iShares Russell 2000 ETFIWM608.39萬0.01%787.4億 USD0.19%US$276.35-0.56%
Vanguard Extended Market ETFVXF498萬0.01%954億 USD0.05%US$231.85-0.72%
State Street SPDR S&P Pharmaceuticals ETFXPH299.94萬0.65%4.69億 USD0.35%US$63.36-1.02%
Vanguard Russell 2000 ETFVTWO251.11萬0.01%180億 USD0.06%US$111.62-0.58%
iShares Russell 2000 Value ETFIWN217萬0.02%137.49億 USD0.24%US$210.44-0.31%
iShares Biotechnology ETFIBB199.49萬0.02%108.2億 USD0.44%US$202.03-1.09%
Schwab U.S. Small-Cap ETFSCHA136.89萬0.01%217.13億 USD0.03%US$32.48-0.55%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
